Immunotherapy for Inhalant Allergy
Introduction
Introduction
- Allergic rhinitis (AR) and allergic asthma (AA) are caused by an immunoglobulin E (IgE) mediated inflammatory response to proteins (or glycoproteins) carried by inhaled organic particles such as pollen, animal dander, mold spores, and/or mite/insect debris.
- Inhalant allergies can be treated by immunotherapy, pharmaceuticals, or by reducing environmental exposure to the allergen.
- Inhalant allergen immunotherapy (AIT) is administered to millions of patients for AR and AA and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT).
- Variability in the initiation and delivery of safe and effective immunotherapy provides opportunities for evidence-based recommendations to improve patient care.
Treatment
...atment...
...viations and Definitions of Common TermsHavi...
...ry of Guideline Key Action Statements (KA...
Assessmen...
...for Allergen ImmunotherapyClinicians shoul...
...d not get Allergen ImmunotherapyClini...
...get Allergen ImmunotherapyClinicians may ch...
...sthma AssessmentClinicians should eva...
...cation...
...Education regarding SLIT versus SCITC...
...tion regarding Preventive Qualitie...
...eatment...
...Pre-/Co-Seasonal TherapyClinicians who admin...
...ing Clinically Relevant AllergensClinicians prescr...
...olysensitized Patients with Limited Allerg...
...ocal Reactions and Allergen Immunotherapy Escalat...
...axis Identification and ManagementThe clinic...
...ting During Allergen ImmunotherapyCl...
...ation for Allergen ImmunotherapyFor patients who a...
...3: Comparison of SCIT and SLIT Modali...
Table 4. World Allergy Organization S...
...Co-Seasonal SLIT Time CourseTime cours...
...2. Anaphylaxis Diagnostic Criteria Reproduced...
...le 5. Differentiating Between Vasovagal and Ana...
.... Management of AnaphylaxisReproduced from the...
...gure 4. Flowchart Showing Key Acti...